We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01917591
Recruitment Status : Completed
First Posted : August 6, 2013
Last Update Posted : March 3, 2017
Information provided by (Responsible Party):
Kerecis Ltd.

Brief Summary:
The objective is to determine, if healing of punch biopsy wounds treated with the fish skin derived MariGen Wound dressing is non-inferior to healing with wounds treated with pig intestines derived Oasis Sheet wound dressing. Secondary endpoints are: Incidence of erythema, Pain, Infection, Quantitative measurements of autoantibodies at baseline and 4 weeks after start of treatment

Condition or disease Intervention/treatment
Punch Biopsy Wounds Healing Times Device: Punch biopsies treated with MariGen Wound ECM dressing Device: Punch biopsies treated with Oasis ECM dressing

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Healing of Punch Graft Wounds With Two Biologic Exracellular Matrices; a Non-inferiority Study
Study Start Date : January 2013
Primary Completion Date : June 2013
Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: MariGen Wound
Fish derived extra cellular matrix
Device: Punch biopsies treated with MariGen Wound ECM dressing
Weekly dressing changes and review of wounds.
Other Name: MariGen Wound ECM wound dressings.
Active Comparator: Oasis Sheet
Pig intestine derived extra cellular matrix
Device: Punch biopsies treated with Oasis ECM dressing
Weekly dressing changes and wound review
Other Name: Oasis ECM wound dressing

Primary Outcome Measures :
  1. wound healing [ Time Frame: 28 days ]
    Time to epithelialisation

Secondary Outcome Measures :
  1. Autoimmune investigations [ Time Frame: 28 days ]
    Measurement of auto-antibodies including anti-collagen I and II antibodies

  2. Incidence of erythema [ Time Frame: 28 days ]
    Number of patients

  3. Pain [ Time Frame: 28 days ]
    number of patients with significant pain

  4. Infection [ Time Frame: 28 days ]
    Number of patients with infections

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • >18 yrs
  • Healthy individual
  • Signature of informed consent

Exclusion Criteria:

  • Autoimmune disease
  • Immunosuppressive treatment
  • Use of addictive drugs
  • Excessive use of alcohol
  • Known fish allergy
  • Known allergy to proteins with porcine origin
  • Peripheral vascular disease
  • Pregnant women
  • Persons receiving anticoagulation therapy or systemic corticosteroids will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01917591

Læknastofur Skipholti
Reykjavik, Iceland, 105
Sponsors and Collaborators
Kerecis Ltd.
Principal Investigator: Hugrun Thorsteinsdottir, MD Derm The National University Hospital of Iceland

Responsible Party: Kerecis Ltd.
ClinicalTrials.gov Identifier: NCT01917591     History of Changes
Other Study ID Numbers: KS-0070
First Posted: August 6, 2013    Key Record Dates
Last Update Posted: March 3, 2017
Last Verified: February 2017

Keywords provided by Kerecis Ltd.:
Biological Dressings
Chronic Disease
Extracellular Matrix
Extra Cellular Matrix
Granulation Tissue
Leg Ulcer
Middle Aged
Prospective Studies
Soft Tissue Injuries
Treatment Outcome
Varicose Ulcer
Wound Healing
Wounds and Injuries

Additional relevant MeSH terms:
Wounds and Injuries